Switching from sildenafil to riociguat for CTEPH
Treatments studied
Part of Lungs & breathing clinical trials.
This trial tests switching from sildenafil to a newer medicine called riociguat for people with CTEPH (a type of lung blood pressure problem) who still have symptoms after a balloon procedure. The goal is to see if the switch helps them feel better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of high blood pressure in the lungs called CTEPH
- You have had a balloon procedure to open blocked arteries in your lungs (BPA) but still have symptoms
- You are currently taking sildenafil (Revatio) and have been on a steady dose for at least 6 weeks
- Your symptoms are noticeable with everyday activities (WHO functional class III)
- You have not been in the hospital for lung or heart problems in the last month
- You are not taking nitrates (like nitroglycerin) and are not pregnant or breastfeeding
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is for people with a type of long-term blood clot in the lungs (CTEPH) who have been taking riociguat for at least 12 weeks. It will see what happens when the medication is stopped, focusing on how the right side of the heart is doing.
This trial tests whether a procedure called balloon pulmonary angioplasty is safe and effective for people with chronic thromboembolic disease in the lungs, especially when surgery isn’t an option. If you have CTEPH, it may help improve lung blood flow and symptoms.
This trial compares what happens when people with chronic thromboembolic pulmonary hypertension (CTEPH) either stop or continue taking the medication riociguat after they have done well following a procedure called balloon pulmonary angioplasty. The goal is to learn whether it is safe and better to stop the medication or keep taking it.
This study looks at how well a medicine called riociguat works for people with pulmonary arterial hypertension when they switch to it from another similar medicine (a PDE5 inhibitor) while already taking two other blood vessel-relaxing medicines. The goal is to see if the switch helps improve their condition over 6 months.
This study tests whether taking injected treprostinil together with riociguat can improve how the heart and lung blood vessels work in people with advanced pulmonary artery hypertension (PAH). It may help improve blood-flow measurements and the structure of the heart.
This study tests whether switching from the oral medicine selexipag to an inhaled medicine called treprostinil can improve symptoms or side effects in people with pulmonary arterial hypertension (PAH). It may be an option if you are not getting enough benefit or are having trouble tolerating selexipag.
Hear when a new Chronic Thromboembolic Pulmonary Hypertension trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.